Safety and efficacy of micafungin in transplantation recipients [1]

Transplantation

Volumn 82, Issue 11, 2006, Pages 1549-

  Forrest, Graeme N ^a,b   Rasetto, Flavia ^a   Akpek, Gorgun ^a   Philosophe, Benjamin ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUCONAZOLE; MICAFUNGIN; RAPAMYCIN; TACROLIMUS;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANDIDIASIS; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; LETTER; PRIORITY JOURNAL; SEPSIS; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS; ORGAN TRANSPLANTATION; PEPTIDES, CYCLIC; STEM CELL TRANSPLANTATION;

EID: 33845719838     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000236029.41292.09     Document Type: Letter

References (5)

1. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805.
2. Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 1018.
3. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391.
4. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171.
5. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407.